A First-of-Its-Kind Platform Targeting CD200 Signaling
OX2’s first-of-its-kind peptide platform, ARL200, received Investigational New Drug authorization from the FDA in 2020, with human clinical trials now underway.
Comprehensive IP Protection
14 issued or pending patents worldwide.
Extensive Preclinical Research
Peer-reviewed publications spanning more than a decade.
Advancing Clinical Development
IND authorization, fast-track status and rare pediatrics disease designation with ongoing Phase I human trials showing encouraging early results.
Deep Scientific Expertise
More than 150+ years of combined oncology and immunology experience across leaders and advisors.
Vaccine-like Injections and a Personalized Tumor Lysate
ARL200 targets CD200—a regulatory protein that helps prevent the immune system from overreacting but can also be exploited by cancer cells to evade immune detection. Unlike conventional checkpoint inhibitors, ARL200 engages both activating and inhibitory CD200 receptor pathways, functioning as a finely tuned regulator of immune response.
Upon binding, the therapy is designed to modulate additional checkpoint pathways—including PD-1, PD-L1, and CTLA-4—toward more optimal levels. This enables antigen-presenting cells to more effectively activate T cells and drive a targeted anti-tumor response.
Our Current Focus: Pediatric Brain Cancer
Consistent with the vision of its founders, OX2 is initially advancing ARL200 for the treatment of select pediatric brain cancers.
In collaboration with Children’s Minnesota, we are completing a Phase I clinical trial involving pediatric and young adult patients with newly diagnosed Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG), as well as patients with recurrent or progressive high-grade glioma (HGG).
A Phase II trial is planned for late 2026, with anticipated support from the Pediatric Neuro-Oncology Consortium.
Plans to Expand ARL200 to Other Cancers
OX2 plans to extend its peptide checkpoint modulation platform across a broad range of cancers, both within and beyond the central nervous system.
Given the widespread role of CD200-mediated immune suppression across tumor microenvironments, OX2 believes its platform may be broadly applicable in cancers where checkpoint dysregulation limits effective immune response.
Collaborators
Breakthroughs in cancer treatment are made possible through strong collaboration. OX2 is proud to work alongside leading research institutions, clinical partners and supporters who share our commitment to advancing new therapies for patients in need.
"We are thrilled to report that patients treated in the trial have had no significant side-effects. They have been thriving and living life to the fullest, and they have hope that this trial might help improve their outcome and that by participating in this trial they are helping future patients."
– Dr. Anne Bendel, Pediatric Oncologist, Children's Minnesota
"Access to a new investigational therapy meant a chance to fight back when standard options were limited."
– Trial Participant
"We know innovation depends on patients willing to participate. Every step forward brings future families more options and more time."